THX Pharma (FRA:3VG) 3-Year RORE % : -53.20% (As of Dec. 2025)


FRA:3VG THX Pharma FRA:3VG
30 GF Score
Price €3.22
! 1 Warning Sign
View Full Analysis

What is THX Pharma 3-Year RORE %?

THX Pharma FRA:3VG +1.10% 30 3-Year RORE % is -53.20 as of Dec. 2025. GuruFocus rates FRA:3VG with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,298 Biotechnology companies, THX Pharma ranks worse than 82.59% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. THX Pharma's 3-Year RORE % for the quarter that ended in Dec. 2025 was -53.20%.

The industry rank for THX Pharma's 3-Year RORE % or its related term are showing as below:

FRA:3VG's 3-Year RORE % is ranked worse than
82.59% of 1298 companies
in the Biotechnology industry
Industry Median: -11.54 vs FRA:3VG: -53.20

THX Pharma  (FRA:3VG) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


THX Pharma 3-Year RORE % Related Terms


THX Pharma 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for THX Pharma's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

THX Pharma 3-Year RORE % Chart

THX Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 -0.77 -15.10 -40.57 -53.20

THX Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.10 -34.71 -40.57 -47.57 -53.20

FRA:3VG vs VRTX, REGN, ALNY: 3-Year RORE % Comparison

For the Biotechnology subindustry, THX Pharma's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


THX Pharma 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, THX Pharma's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where THX Pharma's 3-Year RORE % falls into.


FRA:3VG
30GF Score
THX Pharma FRA:3VG
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

THX Pharma 3-Year RORE % Calculation

THX Pharma's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.252--1.051 )/( -1.502-0 )
=0.799/-1.502
=-53.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -53.20 mean?
THX Pharma (FRA:3VG) has a 3-Year RORE % of -53.20 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on THX Pharma and its competitors. According to the industry distribution chart, THX Pharma ranks #1072 out of 1298 companies in the Biotechnology industry, placing it in the top 82.6%.
Is THX Pharma's 3-Year RORE % too high?
THX Pharma's current 3-Year RORE % is -53.20. Based on the distribution chart, THX Pharma ranks #1072 out of 1298 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, THX Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, THX Pharma ranks #1072 out of 1298 companies for 3-Year RORE %. This places THX Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on THX Pharma and its competitors. THX Pharma's current 3-Year RORE % is -53.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (FRA:3VG) has a current 3-Year RORE % of -53.20. The current 3-Year RORE % is -53.20. THX Pharma's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For THX Pharma (FRA:3VG), the current 3-Year RORE % is -53.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

THX Pharma Business Description

Other Exchanges ALTHX:France3VG:Germany
Address 60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
30GF Score

Get the complete analysis for FRA:3VG

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.22
Price